Case Report: HER2-positive vulvar Paget disease achieving long-term control with trastuzumab-based systemic therapy plus radiotherapy

病例报告:HER2阳性外阴佩吉特病患者接受曲妥珠单抗全身治疗联合放疗后获得长期控制

阅读:5

Abstract

PURPOSE: Vulvar Paget's disease with secondary invasive adenocarcinoma can be challenging to manage, particularly in inoperable or recurrent situations. We report this rare case to raise clinical awareness, accumulate diagnostic and treatment experience, and offer guidance for managing similar cases in the future. METHODS: We present a 79-year-old woman with large invasive vulvar Paget's disease (HER2 3+). RESULTS: As surgery was not feasible, she received trastuzumab plus capecitabine, achieving marked tumor shrinkage. Nine months later, local recurrence with bone metastasis was treated with the same regimen followed by sequential radiotherapy (60 Gy), resulting in partial remission. With trastuzumab maintenance, disease control has been sustained for 17 months. CONCLUSION: HER2-targeted therapy combined with chemotherapy and radiotherapy is a promising treatment strategy for HER2-positive, inoperable or recurrent VPD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。